Prevention and Treatment of Hypertension in Pregnancy

1

Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104. doi: 10.1016/j.preghy.2014.02.001.).

2

American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131. doi: 10.1097/01.AOG.0000437382.03963.88.).

3

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–137. doi: 10.1053/j.semperi.2009.02.010.

4

World Health Organisation . The World Health Report 2005: Make Every Mother and Child Count. Geneva, Switzerland: World Health Organization; 2005.)

5

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–644. doi: 10.1016/S0140-6736(10)60279-6.). 

6

Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, Kenny LC, McCarthy F, Myers J, Poon LC, Rana S, Saito S, Staff AC, Tsigas E, von Dadelszen P. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022 Mar;27:148-169. doi: 10.1016/j.preghy.2021.09.008. Epub 2021 Oct 9. PMID: 35066406.).

7

Frequency of Hypertension Associated with Pregnancy among The Pregnant Women Attending Maternal and Child Care Centers in Belbeis City. The Egyptian Journal of Community Medicine, 2017; 35(3): 83-91.

8

SOMANZ hypertension in pregnancy guideline 2023. https://www.somanz.org/hypertension-in-pregnancy-guideline-2023/. Accessed February 2025

9

1. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]. London: NICE; 2023 Jun [updated 2023 Jun; cited 2024 Month Day]. Available from: https://www.nice.org.uk/guidance/ng133

10

Magee LA, Smith GN, Bloch C, Côté AM, Jain V, Nerenberg K, von Dadelszen P, Helewa M, Rey E. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022 May;44(5):547-571.e1. doi: 10.1016/j.jogc.2022.03.002. PMID: 35577426

11

Queensland Clinical Guideline: Hypertension and pregnancy 2021. Accessed February 2025

12

Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2021;27:148-169. doi:10.1016/j.preghy.2021.09.008.

13

ACOG Practice Bulletin 222 (2020) Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology, 135, e237-e260

14

Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014 Apr;4(2):105-45. doi: 10.1016/j.preghy.2014.01.003. Epub 2014 Feb 25. PMID: 26104418

15

R. Akaishi, T. Yamada, M. Morikawa, R. Nishida, H. Minakami, Clinical features of isolated gestational proteinuria progressing to pre-eclampsia: retrospective observational study, BMJ Open 4 (2014), e004870.

16

Phelan LK, Brown MA, Davis GK, Mangos G. A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia. Hypertens Pregnancy 2004;23:135–42. (Level II-3)

17

North RA, Taylor RS, Schellenberg JC. Evaluation of a definition of pre-eclampsia. Br J Obstet Gynaecol 1999;106:767–73 (Level II-2)

18

M.Y. Tan, D. Wright, L. Koutoulas, R. Akolekar, K.H. Nicolaides, Comparison of screening for pre-eclampsia at 31–34 weeks’ gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF, Ultrasound Obstet. Gynecol. 49 (2017) 201–208

19

US Preventive Services Task Force. Screening for Preeclampsia. In: DiGiuseppi C, Atkins D, Woolf S, et al. (eds). Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD: Williams and Wilkins; 1996. p. 419-24

20

Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778-786

21

Higgins JR, de SwietM. Blood-pressure measurement and classification in pregnancy. Lancet. 2001;357(9250):131-135.

22

Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716

23

Park HJ, Shim SS, Cha DH. Combined screening for early detection of pre-eclampsia. International Journal of Molecular Sciences 2015;16(8):17952-74.

24

Ramos JGR, Ranzani OT, Perondi B, Dias RD, Jones D, Carvalho CRR, et al. A decision-aid tool for ICU admission triage is associated with a reduction in potentially inappropriate intensive care unit admissions. J Crit Care. 2019;51:77–83

25

T.J. Cade, P.C. de Crespigny, T. Nguyen, J.R. Cade, M.P. Umstad, Should the spot albumin-to-creatinine ratio replace the spot protein-to-creatinine ratio as the primary screening tool for proteinuria in pregnancy? Pregnancy Hypertens. 5 (2015) 298–302

26

A.M. Cote, M.A. Brown, E. Lam, et al., Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in Hypertensive pregnant women: systematic review, BMJ 336 (2008) 1003–1006

27

P.J. Saudan, M.A. Brown, T. Farrell, L. Shaw, Improved methods of assessing proteinuria in hypertensive pregnancy, Br. J. Obstet. Gynaecol. 104 (1997) 1159–1164

28

J. Waugh, R. Hooper, E. Lamb, et al., Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis, Health Technol. Assess. 21 (2017) 1–90

29

Sonek J, Krantz D, Carmichael J, Downing C, Jessup K, Haidar Z, et al. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume. Am J Obstet Gynecol. 2018;218(1):126.e1-.e13

30

Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15

31

Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers:results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743-50

32

Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. 2019; 145(S1):1-33

33

Patil M, Panchanadikar TM, Wagh G. Variation of PAPP-A level in the first trimester of pregnancy and its clinical outcome. Journal of Obstetrics and Gynaecology of India. [Internet]. 2014 [cited 2020 July 9]; 64(2):116-9 DOI:10.1007/s13224-013-0481-4

34

Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, doubleblind, placebo-controlled trial. 2020; 395(10220):285-93

35

Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre‐eclampsia and its complications. Cochrane Database of Systematic Reviews. [Internet]. 2019; DOI:10.1002/14651858.CD004659.pub3

36

Miciak-Ławicka E, Begier-Krasińska B, Tykarski A, Krasiński Z. Does the timing of aspirin administration influence its antiplatelet effect - review of literature on chronotherapy. Polish journal of cardio-thoracic surgery 2018;15(2):125-9.

37

Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 2018;218(3):287-93

38

Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985;1(8433):840-2

39

CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet (London, England). 1994;343(8898):619-29

40

Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomized trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105(3):286-92

41

Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338(11):701-5

42

Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015;46(4):419-23

43

Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613-22.

44

Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216(2):121-8 e2

45

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstetrics and gynecology. 2010;116(2 Pt 1):402-14

46

Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110-20 e6

47

Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013;30(1-2):260-79

48

Hofmeyr GJ, Lawrie TA, Atallah Á, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018;10:CD001059.

49

G.J. Hofmeyr, A.P. Betran, M. Singata-Madliki, et al., Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial, Lancet 393 (2019) 330–339.

50

Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N, et al. World Health Organization Randomised trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol. 2006;194(3):639-49.

51

Society for Maternal-Fetal Medicine. SMFM Consult Series #59: Patient counseling for preeclampsia. Am J Obstet Gynecol. 2023;228(4):B15-B24. doi:10.1016/j.ajog.2023.02.002.

52

ACOG Committee Opinion No. 736 (2023 Update). Obstet Gynecol. 2023;141(2):e1-e12.

53

WHO Standards for Maternal Education (2021). WHO Recommendations on Antenatal Care (2021), p.87.

54

MOTHER RCT (AJOG 2022). Am J Obstet Gynecol. 2022;226(4):S1-S10.

55

Global Preeclampsia Registry (2023). Hypertension. 2023;81(3):e25-e33.

56

Magdy Mohamed Amin, Mohamed Sabry Ibrahim, et al. Three Delays Model to Maternal Mortality Scenarios at Sohag Univeristy Hospital Bidirectional Cohort Study 2021. The Egyptian Journal of Hospital Medicine (April 2021) Vol. 83, Page 812-816.

57

 Weissgerber TL, Wolfe LA, Davies GA. The role of regular physical activity in preeclampsia prevention. Med Sci Sports Exerc. 2004;36(12):2024-31.

58

Clapp JF. The effects of maternal exercise on fetal oxygenation and fetoplacental growth. Eur J Obstet Gynecol Reprod Biol. 2003;110 Suppl 1:S80-5.

59

 Barakat R, Refoyo I, Coteron J, Franco E. Exercise during pregnancy has a preventative effect on excessive maternal weight gain and gestational diabetes. A Randomised controlled trial. Braz J Phys Ther. 2019;23(2):148-55.

60

da Silva SG, Hallal PC, Domingues MR, Bertoldi AD, Silveira MFD, Bassani D, et al. A Randomised controlled trial of exercise during pregnancy on maternal and neonatal outcomes: results from the PAMELA study. Int J Behav Nutr Phys Act. 2017;14(1):175.

61

de Oliveria Melo AS, Silva JL, Tavares JS, Barros VO, Leite DF, Amorim MM. Effect of a physical exercise program during pregnancy on uteroplacental and fetal blood flow and fetal growth: a Randomised controlled trial. Obstet Gynecol. 2012;120(2 Pt 1):302-10.

62

 Ruiz JR, Perales M, Pelaez M, Lopez C, Lucia A, Barakat R. Supervised exercise-based intervention to prevent excessive gestational weight gain: a Randomised controlled trial. Mayo Clin Proc. 2013;88(12):1388-97.

63

Tomić V, Sporiš G, Tomić J, Milanović Z, Zigmundovac-Klaić D, Pantelić S. The effect of maternal exercise during pregnancy on abnormal fetal growth. Croat Med J. 2013;54(4):362-8.

64

Wang C, Wei Y, Zhang X, Zhang Y, Xu Q, Sun Y, et al. A Randomised clinical trial of exercise during pregnancy to prevent gestational diabetes mellitus and improve pregnancy outcome in overweight and obese pregnant women. Am J Obstet Gynecol. 2017;216(4):340-51.

65

Jayashree R, Malini A, Rakhshani A, Nagendra H, Gunasheela S, Nagarathna R. Effect of the integrated approach of yoga therapy on platelet count and uric acid in pregnancy: A multicenter stratified Randomised single-blind study. Int J Yoga. 2013;6(1):39-46.

66

Rakhshani A, Nagarathna R, Mhaskar R, Mhaskar A, Thomas A, Gunasheela S. The effects of yoga in prevention of pregnancy complications in high-risk pregnancies: a Randomised controlled trial. Prev Med. 2012;55(4):333-40.

67

Kasawara KT, Burgos CS, do Nascimento SL, Ferreira NO, Surita FG, Pinto E Silva JL. Maternal and Perinatal Outcomes of Exercise in Pregnant Women with Chronic Hypertension and/or Previous Preeclampsia: A Randomised Controlled Trial. ISRN Obstet Gynecol. 2013;2013:857047.

68

 Gennari-Moser C, Escher G, Kramer S, Dick B, Eisele N, Baumann M, et al. Normotensive blood pressure in pregnancy: the role of salt and aldosterone. Hypertension. 2014;63(2):362-8.

69

Farese S, Shojaati K, Kadereit B, Frey FJ, Mohaupt MG. Blood pressure reduction in pregnancy by sodium chloride. Nephrol Dial Transplant. 2006;21(7):1984-7.

70

Duley L, Henderson-Smart D, Meher S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev. 2005(4):CD005548.

71

Delemarre FM, van Leest LA, Jongsma HW, Steegers EA. Effect of low-sodium diet on uteroplacental circulation. J Matern Fetal Med. 2000;9(4):197-200.

72

van Buul BJ, Steegers EA, Jongsma HW, Rijpkema AL, Eskes TK, Thomas CM, et al. Dietary sodium restriction in the prophylaxis of hypertensive disorders of pregnancy: effects on the intake of other nutrients. Am J Clin Nutr. 1995;62(1):49-57.

73

Middleton P, Gomersall JC, Gould JF, Shepherd E, Olsen SF, Makrides M. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev. 2018;11:CD003402.

74

Rani A, Wadhwani N, Chavan-Gautam P, Joshi S. Altered development and function of the placental regions in preeclampsia and its association with long-chain polyunsaturated fatty acids. Wiley Interdiscip Rev Dev Biol. 2016;5(5):582-97.

75

 Kulkarni AV, Mehendale SS, Yadav HR, Joshi SR. Reduced placental docosahexaenoic acid levels associated with increased levels of sFlt-1 in preeclampsia. Prostaglandins Leukot Essent Fatty Acids. 2011;84(1-2):51-5.

76

 Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, et al. Do pregnant women report use of dispensed medications? Epidemiology. 2001;12(5):497-501.

77

Onwude JL, Lilford RJ, Hjartardottir H, Staines A, Tuffnell D. A randomized double blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol. 1995;102(2):95-100

78

Horvaticek M, Djelmis J, Ivanisevic M, Oreskovic S, Herman M. Effect of eicosapentaenoic acid and docosahexaenoic acid supplementation on C-peptide preservation in pregnant women with type-1 diabetes: Randomised placebo controlled clinical trial. Eur J Clin Nutr. 2017;71(8):968-72.

79

Amin G SAZ, Jafariazar Z , Vosoogh S, Shariat M, et al. The effect of garlic capsule on the prevention of preeclampsia in high-risk Turkmen pregnant women. J undishapur J Nat Pharm Prod2020.

80

Ziaei S, Hantoshzadeh S, Rezasoltani P, Lamyian M. The effect of garlic tablet on plasma lipids and platelet aggregation in nulliparous pregnants at high risk of preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2001;99(2):201-6.

81

Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot Randomised controlled trial. Am J Obstet Gynecol. 2016;214(6):720.e1-.e17..

82

Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL. Preeclampsia and antioxidant nutrients: decreased plasma levels of reduced ascorbic acid, alpha-tocopherol, and beta-carotene in women with preeclampsia. Am J Obstet Gynecol. 1994;171(1):150-7.

83

Chappell LC, Seed PT, Kelly FJ, Briley A, Hunt BJ, Charnock-Jones DS, et al. Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am J Obstet Gynecol. 2002;187(3):777-84.

84

Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354(9181):810-6.

85

 Chan AC. Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol. 1993;71(9):725-31.

86

Araújo CAL, Lorena SB, Cavalcanti GCS, Leão GLS, Tenório GP, Alves JGB. Oral magnesium supplementation for leg cramps in pregnancy-An observational controlled trial. PLoS One. 2020;15(1):e0227497.

87

Bullarbo M, Mattson H, Broman AK, Ödman N, Nielsen TF. Magnesium Supplementation and Blood Pressure in Pregnancy: A Double-Blind Randomised Multicenter Study. J Pregnancy. 2018;2018:4843159.

88

D’Almeida A, Carter JP, Anatol A, Prost C. Effects of a combination of evening primrose oil (gamma linolenic acid) and fish oil (eicosapentaenoic + docahexaenoic acid) versus magnesium, and versus placebo in preventing pre-eclampsia. Women Health. 1992;19(2-3):117-31.

89

Martin RW, Perry KG, Hess LW, Martin JN, Morrison JC. Oral magnesium and the prevention of preterm labor in a high-risk group of patients. Am J Obstet Gynecol. 1992;166(1 Pt 1):144-7.

90

Sibai BM, Villar MA, Bray E. Magnesium supplementation during pregnancy: a double-blind Randomised controlled clinical trial. Am J Obstet Gynecol. 1989;161(1):115-9.

91

Spätling L, Spätling G. Magnesium supplementation in pregnancy. A double-blind study. Br J Obstet Gynaecol. 1988;95(2):120-5.

92

Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357(5):454-61.

93

 Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and metaanalysis. Lancet. 2009;373(9680):2034-40.

94

de Alwis N, Beard S, Mangwiro YT, Binder NK, Kaitu’u-Lino TJ, Brownfoot FC, et al. Pravastatin as the statin of choice for reducing pre-eclampsia associated endothelial dysfunction. Pregnancy Hypertens. 2020;20:83-91.

95

 Pánczél Z, Kukor Z, Supák D, Kovács B, Kecskeméti A, Czizel R, et al. Pravastatin induces NO synthesis by enhancing microsomal arginine uptake in healthy and preeclamptic placentas. BMC Pregnancy Childbirth. 2019;19(1):426.

96

Wang GJ, Yang Z, Huai J, Xiang QQ. Pravastatin alleviates oxidative stress and decreases placental trophoblastic cell apoptosis through IL-6/STAT3 signaling pathway in preeclampsia rats. Eur Rev Med Pharmacol Sci. 2020;24(24):12955-62.

97

 Döbert M, Varouxaki AN, Mu AC, Syngelaki A, Ciobanu A, Akolekar R, et al. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation. 2021;144(9):670-9.

98

Singh S, Sinha R, Kaushik M. Prophylactic Low Molecular Weight Heparin Improving Perinatal Outcome in Non-thrombophilic Placental-Mediated Complications. J Obstet Gynaecol India. 2016;66(6):436-40.

99

Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45(1):86-91.

100

Gris JC, Chauleur C, Molinari N, Marès P, Fabbro-Peray P, Quéré I, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011;106(6):1053-61.

101

Haddad B, Winer N, Chitrit Y, Houfflin-Debarge V, Chauleur C, Bages K, et al. Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomised Controlled Trial. Obstet Gynecol. 2016;128(5):1053-63.

102

Groom KM, McCowan LM, Mackay LK, Lee AC, Said JM, Kane SC, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a Randomised trial. Am J Obstet Gynecol. 2017;216(3):296.e1-.e14.

103

Llurba E, Bella M, Burgos J, Mazarico E, Gómez-Roig MD, De Diego R, et al. Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomised Trial. Fetal Diagn Ther. 2020;47(11):824-33.

104

Sergio F, Maria Clara D, Gabriella F, Giorgia S, Sara De Carolis, Giancarlo P, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy. 2006;25(2):115-27.

105

Abdel Razik M, El-Berry S, Abosereah M, Edris Y, Sharafeldeen A. Prophylactic treatment for preeclampsia in high-risk teenage primigravidae with nitric oxide donors: a pilot study. J Matern Fetal Neonatal Med. 2016;29(16):2617-20.

106

Camarena Pulido EE, García Benavides L, Panduro Barón JG, Pascoe Gonzalez S, Madrigal Saray AJ, García Padilla FE, et al. Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, Randomised, clinical trial. Hypertens Pregnancy. 2016;35(2):217-25.

107

 Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a Randomised double-blind placebo-controlled trial. Ultrasound Obstet Gynecol. 1998;12(5):334-8

108

Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):778-86.

109

Nascimento IBD, Sales WB, Dienstmann G, Souza MLR, Fleig R, Silva JC. Metformin for prevention of cesarean delivery and large-for-gestational-age newborns in non-diabetic obese pregnant women: a Randomised clinical trial. Arch Endocrinol Metab. 2020;64(3):290-7.

110

 Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med. 2016;374(5):434-43.

111

Pérez-López FR, Pasupuleti V, Mezones-Holguin E, Benites-Zapata VA, Thota P, Deshpande A, et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of Randomised controlled trials. Fertil Steril. 2015;103(5):1278-88.e4.

112

Ramos-Trautmann G, González L, Díaz-Luquis G, Pérez CM, Palacios C. Inverse Association between Vitamin D Status and Diabetes in a Clinic Based Sample of Hispanic Adults in Puerto Rico. Diabetes Res (Fairfax). 2015;1(1):5-11.

113

Choi A, Noh Y, Park SH, Choe SA, Shin JY. Exploration of Proton Pump Inhibitors Use During Pregnancy and Preeclampsia. JAMA Netw Open. 2021;4(9):e2124339.

114

Hastie R, Bergman L, Cluver CA, Wikman A, Hannan NJ, Walker SP, et al. Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women. Hypertension. 2019;73(5):1097-103.

115

World Health Organization. WHO recommendations on maternal and newborn care for a positive postnatal experience. Geneva: World Health Organization; 2022. Available from: https://www.who.int/publications/i/item/9789240045989

116

Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015 Jan 29;372(5):407-17. doi: 10.1056/NEJMoa1404595.

117

van Oostwaard MF, Langenveld J, Schuit E, Bekedam DJ, Bloemenkamp KWM, van den Akker ESA, et al. Hypertensive disorders of pregnancy: recurrence and long-term maternal health. Am J Obstet Gynecol. 2015 Jan;212(1):62.e1-62.e17. doi:10.1016/j.ajog.2014.07.015. PMID: 25025935.

118

1. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia [Internet]. Geneva: World Health Organization; 2021 [cited 2024 Month Day]. Available from: https://www.who.int/publications/i/item/9789240045989

119

Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The International Society for the Study of Hypertension in Pregnancy (ISSHP) guideline for the management of hypertensive disorders of pregnancy. Pregnancy Hypertens. 2023;32:100215. doi:10.1016/j.preghy.2023.100215.

120

WHO recommendations on drug treatment for non-severe hypertension in pregnancy. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Available from: https://www.who.int/publications/i/item/9789240008435

121

Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark EAS, et al. Treatment for mild chronic hypertension during pregnancy: secondary analysis of the CHAP Trial. Lancet Glob Health. 2023 Apr;11(4):e512-e523. doi:10.1016/S2214-109X(23)00042-3. PMID: 36925172.

122

FIGO Safe Motherhood and Newborn Health Committee. FIGO statement: Resource-stratified guidelines for hypertensive disorders of pregnancy. Int J Gynaecol Obstet. 2023;160(S1 Suppl 1):S26–S29. doi:10.1002/ijgo.14540.

123

Kumar M., Meena J., Gupta U., Singh A., Jain N. Management of early onset severe preeclampsia in a tertiary hospital in India: Does expectant management alter perinatal outcome? Indian J. Med. Sci. 2011;65:535–542. doi: 10.4103/0019-5359.109903.

124

Sarsam D.S., Shamden M., Al Wazan R. Expectant versus aggressive management in severe preeclampsia remote from term. Singap. Med. J. 2008;49:698–703.

125

Abdel-Hady E.-S., Fawzy M., El-Negeri M., Nezar M., Ragab A., Helal A.S. Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings? Arch. Gynecol. Obstet. 2010;282:23–27. doi: 10.1007/s00404-009-1209-7.

126

Kluger Y, Ben-ishay O, Sartelli M, Ansaloni L, Abbas AE, Agresta F, et al. World society of emergency surgery study group initiative on timing of acute care surgery classification (TACS) World J Emerg Surg. 2013;8(1):17. doi: 10.1186/1749-7922-8-17.

127

Inta A, Tongsong T, Srisupundit K. Pregnancy Outcomes of Conservative Management in Preeclampsia with Severe Features. J Clin Med. 2023 Oct 4;12(19):6360. doi: 10.3390/jcm12196360. PMID: 37835004; PMCID: PMC10573983.

128

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1–22.

129

Sibai BM. Management of late preterm and early-term pregnancies complicated by mild gestational hypertension/pre-eclampsia. Semin Perinatol 2011;35:292–6.

130

C.A. Crowther, A.M. Bouwmeester, H.M. Ashurst, Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? Br. J. Obstet. Gynaecol. 99 (1992) 13–17.

131

M.F. Mottola, M.H. Davenport, S.M. Ruchat, et al. No. 367-2019 Canadian Guideline for Physical Activity throughout Pregnancy. J. Obstet. Gynaecol. Can. 2018;40:1528-37.

132

Society for Maternal-Fetal Medicine (SMFM). SMFM Consult Series #58: Use of antenatal corticosteroids. Am J Obstet Gynecol. 2023 Apr;228(4):B10-B20. doi:10.1016/j.ajog.2023.02.001. PMID: 36763933.

133

Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation in women at risk of preterm birth. Cochrane Database Syst Rev. 2017 Mar 13;3:CD004454. doi:10.1002/14651858.CD004454.pub3. PMID: 28288288.

134

Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth. NEJM. 2019;380(11):1027-1037.

135

Balogun OA, Sibai BM. Counseling, management, and outcome in women with severe preeclampsia at 23 to 28 weeks’ gestation. Clin Obstet Gynecol 2017;60:183–9.

136

World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes – 2023 update [Internet]. Geneva: World Health Organization; 2023 [cited 2024 Month Day]. Available from: https://www.who.int/publications/i/item/9789240062658

137

 Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med. 2016;374(14):1311-1320.

138

 McKinlay CJ, Crowther CA, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth. Cochrane Database Syst Rev. 2023;3:CD004454.

139

Chappell LC, Brocklehurst P, Green ME, et al. Planned early delivery versus expectant management for preterm preeclampsia. Lancet. 2019;394(10204):1181-1190.

140

Crowther CA, Middleton PF, Voysey M, et al. Magnesium sulphate for fetal neuroprotection in preterm birth: an updated meta-analysis. Lancet. 2023;401(10375):451-462.

141

Rouse DJ, Hirtz DG, Thom E, et al. Long-term outcomes after antenatal MgSO₄ in preterm infants. JAMA Pediatr. 2021;175(6):e210007.

142

Koopmans CM, Bijlenga D, Groen H, Vijgen SMC, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009 Sep 19;374(9694):979-88. doi:10.1016/S0140-6736(09)60736-4. PMID: 19656558.

143

Cluver C, Novikova N, Koopmans CM, West HM. Interventions for treating pre-eclampsia: a Cochrane systematic review update. Cochrane Database Syst Rev. 2022 Mar 14;3:CD009109. doi:10.1002/14651858.CD009109.pub3. PMID: 35286508.

144

Society for Maternal-Fetal Medicine (SMFM). Expectant management versus delivery in term preeclampsia: a systematic review. Am J Obstet Gynecol. 2021 Feb;224(2):S678-S679. doi:10.1016/j.ajog.2020.12.1232.

145

Broekhuijsen K, van Baaren GJ, van Pampus MG, Ganzevoort W, Sikkema JM, Woiski MD, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial. N Engl J Med. 2019 Mar 14;380(11):1027-37. doi:10.1056/NEJMoa1813480. PMID: 30865774.

146

Vigil-De Gracia P, Ludmir J, Ng J, Soto E, Alvarado-Duran A, Vallejos-Gómez J, et al. Expectant management of preeclampsia remote from term: The FLAME study. Am J Obstet Gynecol. 2020 Jun;222(6):606.e1-606.e15. doi:10.1016/j.ajog.2020.01.018. PMID: 31954120.

147

Society for Maternal-Fetal Medicine (SMFM). SMFM Consult Series #64: Preeclampsia with severe features at late preterm gestations. Am J Obstet Gynecol. 2022 Apr;226(4):B2-B14. doi:10.1016/j.ajog.2022.02.001. PMID: 35314033.

148

Smith JM, Lowe RF, Fullerton J, et al. Anticonvulsants for pre-eclampsia. Cochrane Database Syst Rev. 2023;3:CD004454. doi:10.1002/14651858.CD004454.pub4.

149

Estcourt LJ, Malouf R, Hopewell S, Doree C, Van Veen J. Prophylactic platelet transfusions prior to surgery for people with thrombocytopenia. Cochrane Database Syst Rev. 2022;3:CD012779. doi:10.1002/14651858.CD012779.pub3.

150

Society for Maternal-Fetal Medicine. SMFM Consult Series #47: Hematologic conditions in pregnancy. Am J Obstet Gynecol. 2021;224(4):B2-B28. doi:10.1016/j.ajog.2020.11.038.

151

Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP syndrome. Cochrane Database Syst Rev. 2021;5:CD008148. doi:10.1002/14651858.CD008148.pub5.

152

Gibbons C, O’Reilly M, Benedetti TJ, et al. SMFM Consult Series #64: Systemic hypertension in pregnancy. Am J Obstet Gynecol. 2022;227(4):B2-B26. doi:10.1016/j.ajog.2022.06.001.

153

Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103(5 Pt 1):981-91. doi:10.1097/01.AOG.0000126245.35811.2a.

154

Juliana Perez Botero, Jennifer Jury McIntosh; Labor and delivery: DIC, HELLP, preeclampsia. Hematology Am Soc Hematol Educ Program 2023; 2023 (1): 737–744.

155

Fonseca JE, Mendez F, Cataño C, et al. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. BJOG. 2005;112(2):211-215. doi:10.1111/j.1471-0528.2004.00333.x.

156

Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015;70 Suppl 1:78–86, e27–e28. doi:10.1111/anae.12913

157

Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994. doi:10.1111/jth.14578.

158

Royal College of Obstetricians and Gynaecologists. Major Obstetric Haemorrhage and Coagulopathy (Green-top Guideline No. 47). London: RCOG; 2022 [cited 2024 Jun 10]. Available from: https://www.rcog.org.uk

159

Hunt BJ, Allard S, Keeling D, et al. A practical guideline for the haematological management of major haemorrhage. Br J Haematol. 2015;170(6):788-803. doi:10.1111/bjh.13580.

160

Franchini M, Marano G, Veropalumbo E, et al. The use of fibrinogen concentrate for the management of trauma-related bleeding: a systematic review and meta-analysis. Blood Transfus. 2021;19(6):463-475. doi:10.2450/2021.0239-20.

161

Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2018;6:15. doi:10.1186/s40560-018-0287-7.

162

Norwitz ER. Preeclampsia: management and prognosis. [Internet]. Waltham MA: UpToDate Inc; 2020 [cited 2020 May 5]. Available from: https://www.uptodate.com

163

Alanis MC, Robinson CJ, Hulsey TC, Ebeling M, Johnson DD. Early-onset severe preeclampsia: induction of labor vs elective cesarean delivery and neonatal outcomes. Am J Obstet Gynecol 2008;199:262.e1–6. (Level II-3)

164

Blackwell SC, Redman ME, Tomlinson M, Landwehr JB Jr, Tuynman M, Gonik B, et al. Labor induction for the preterm severe pre-eclamptic patient: is it worth the effort? J Matern Fetal Med 2001;10:305–11. (Level II-3)

165

Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Publications Committee, Society for Maternal–Fetal Medicine. Am J Obstet Gynecol 2011;205:191–8. (Level III)

166

Who recommendations for prevention and treatment of preeclampsia and eclampsia, Implications and Actions; 2013

167

Audibert F, Friedman SA, Fréchette L, et al. Clinical practice guideline: management of hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2018;40(7):e542-e571. doi:10.1016/j.jogc.2018.05.004.

168

American College of Obstetricians and Gynecologists. Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203. Obstet Gynecol. 2022;139(1):e1-e19. doi:10.1097/AOG.0000000000004600.

169

World Health Organization. WHO recommendation on aspirin for prevention of preeclampsia. Geneva: WHO; 2020 [cited 2024 Jun 10]. Available from: https://www.who.int/publications/i/item/9789240007789

170

American College of Obstetricians and Gynecologists. Physical activity and exercise during pregnancy and the postpartum period. ACOG Committee Opinion No. 804. Obstet Gynecol. 2020;135(4):e178-e188. doi:10.1097/AOG.0000000000003772.

171

Royal College of Obstetricians and Gynaecologists. Good Practice No. 11: Reducing Risks in Pregnancy. London: RCOG; 2019 [cited 2024 Jun 10]. Available from: https://www.rcog.org.uk

172

Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia. Circulation. 2019;140(3):225-235. doi:10.1161/CIRCULATIONAHA.118.038080.

173

Magee LA, von Dadelszen P, Singer J, et al. Do labetalol and methyldopa impact pregnancy outcomes? Secondary analysis of the CHIPS trial. BJOG. 2017;124(1):11-21. doi:10.1111/1471-0528.14110.

174

Cruz MO, Gao W, Hibbard JU. What is the optimal time for delivery in women with gestational hypertension? Am J Obstet Gynecol 2012;207:214 e1e6

175

Ram M, Berger H, Geary M, et al. Timing of Delivery in Women With Chronic Hypertension. Obstet Gynecol 2018;132:669e77.

176

Hutcheon JA, Lisonkova S, Magee LA, et al. Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG 2011;118:49e54.

177

Leduc D, Senikas V, Lalonde AB. No. 235-Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage. J Obstet Gynaecol Can 2018;40:e841-55.

178

Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2014;36(5):416-441. doi:10.1016/S1701-2163(15)30588-0

179

Association of Anaesthetists of Great Britain and Ireland. Guidelines for the management of severe pre-eclampsia. Anaesthesia. 2011;66(10):943-949. doi:10.1111/j.1365-2044.2011.06861.x

180

National Institute for Health and Care Excellence. Intrapartum care for healthy women and babies [CG190]. London: NICE; 2019 [updated 2022; cited 2024 Jun 10]. Available from: https://www.nice.org.uk/guidance/cg190

181

World Health Organization. WHO recommendations for prevention and treatment of postpartum haemorrhage. Geneva: WHO; 2018 [cited 2024 Jun 10]. Available from: https://www.who.int/publications/i/item/9789241550425

182

 Brown MC, Best KE, Pearce MS, et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2018;33(5):763-771. doi:10.1007/s10654-018-0376-x.

183

Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2014;36(5):416-441. doi:10.1016/S1701-2163(15)30588-0.

184

American Academy of Pediatrics. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-e841. doi:10.1542/peds.2011-3552.

185

Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2018;125(13):1642-1654. doi:10.1111/1471-0528.15394.

186

Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women. Circulation. 2011;123(11):1243-1262. doi:10.1161/CIR.0b013e31820faaf8.

187

Staff AC, Redman CWG, Williams D, et al. Pregnancy and long-term maternal cardiovascular health: progress through harmonization of research cohorts and biobanks. Hypertension. 2019;73(2):318-326. doi:10.1161/HYPERTENSIONAHA.118.12223.

188

Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2):e003497. doi:10.1161/CIRCOUTCOMES.116.003497.